Skip to main content

Table 6 Adverse events reported by ≥ 2% of subjects in any treatment group (ITT population), n (%)

From: A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

Latanoprost concentration (μg/mL)
  50 75 100 125
N 71 70 72 69
Eye disorders
 Abnormal sensation in eye 3 (4.2) 4 (5.7) 7 (9.7) 4 (5.8)
 Anterior chamber disorder NOS 0 (0.0) 2 (2.9) 2 (2.8) 1 (1.4)
 Conjunctival disorder NOS 2 (2.8) 1 (1.4) 0 (0.0) 0 (0.0)
 Conjunctival edema 0 (0.0) 2 (2.9) 2 (2.8) 0 (0.0)
 Conjunctival hyperemia 12 (16.9) 13 (18.6) 15 (20.8) 11 (15.9)
 Dry eye NEC 1 (1.4) 2 (2.9) 4 (5.6) 0 (0)
 Eye irritation 5 (7.0) 7 (10.0) 6 (8.3) 8 (11.6)
 Eye pain 2 (2.8) 6 (8.6) 3 (4.2) 4 (5.8)
 Eyelid disorder NOS 0 (0.0) 2 (2.9) 0 (0.0) 0 (0.0)
 Keratitis NEC 2 (2.8) 4 (5.7) 3 (4.2) 3 (4.3)
 Ocular hyperemia* 5 (7.0) 4 (5.7) 5 (6.9) 2 (2.9)
 Red eye 3 (4.2) 5 (7.1) 6 (8.3) 2 (2.9)
 Vision blurred 1 (1.4) 0 (0.0) 2 (2.8) 3 (4.3)
Musculoskeletal, connective tissue and bone disorders
 Arthralgia 1 (1.4) 0 (0.0) 2 (2.8) 1 (1.4)
Nervous system disorders
 Headache NOS 4 (5.6) 4 (5.7) 3 (4.2) 4 (5.8)
  1. ITT intention-to-treat, NEC not elsewhere classified, NOS not otherwise specified.
  2. *Includes conjunctival hyperemia where investigator specified it as bulbar or palpebral.